Abstract
O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that removes alkyl-adducts from the O6-guanine in DNA and is a crucial defense against O6-alkylating agent-induced cytotoxicity. We demonstrated here that two camptothecin (CPT)-resistant cell lines (CPT30 and KB100) were more sensitive to N,N′-bis(2-chloroethyl)-N-nitrosurea (BCNU) than their parental cells. Enhanced sensitivity to BCNU in these two CPT-resistant cells involved transcriptional repression of the MGMT gene. The mechanism of MGMT gene down-regulation in CPT-resistant cells was not through gene abnormality, mRNA stability, and CpG island hypermethylation. However, the high level of methyl-CpG-binding protein 2 (MeCP2) and dimethylation of H3K9 in the promoter region were found in CPT30 and KB100 cells. Furthermore, increased MeCP2 binding on MGMT promoter was also found to be correlated with MGMT gene-silencing in short-term CPT treatment; thus, enhanced BCNU sensitivity was found in CPT-treated cells. Taken together, we suggest that CPT is able to suppress the transcription of the MGMT gene through recruiting of MeCP2 and H3K9 dimethylation, thus causing a synergistic interaction with BCNU. These findings provide a possible explanation regarding why the combination of CPT and BCNU results in a better objective response than single-use alone. In addition, this study supports a new indication for treating patients who are receiving refractory CPT derivatives with BCNU.
Footnotes
-
This work was supported by intramural grants CA-096-PP-03 from the National Health Research Institutes, Taipei, and the National Science Council (NSC 96-2752-B-400-001-PAE), Taipei, Taiwan, Republic of China.
-
L.-C.M. and C.-C.K. contributed equally to this work.
-
ABBREVIATIONS: Top, topoisomerase; 5-aza-dC, 5-aza-2′-deoxycytidine; BCNU, N,N′-bis(2-chloroethyl)-N-nitrosurea; ChIP, chromatin immunoprecipitation; CI, combination index; CPT, camptothecin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H3Ac, acetylation of lysine residues on histone H3; H3K4me2, dimethylation of lysine 4 on histone H3; H3K9me2, dimethylation of lysine 9 on histone H3; H4Ac, acetylation of lysine residues on histone H4; MBD, methyl-CpG binding domain; MeCP2, methyl-CpG-binding protein 2; MGMT, O6-methylguanine-DNA methyltransferase; PBMC, peripheral blood mononuclear cell; PCR, polymerase chain reaction; Q-PCR, real-time quantitative polymerase chain reaction; SDS, sodium dodecyl sulfate; TSA, trichostatin A; bp, base pair; nt, nucleotide; SN38, 7-ethyl-10-hydroxycamptothecin.
-
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received November 25, 2007.
- Accepted May 20, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|